The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) represents a significant advancement over its 2007 predecessor, incorporating molecular parameters alongside histological features to define many tumor entities. This update restructures diffuse gliomas, medulloblastomas, and other embryonal tumors, and introduces new entities defined by both histology and molecular features. Key changes include the addition of brain invasion as a criterion for atypical meningioma and a soft tissue-type grading system for solitary fibrous tumor/hemangiopericytoma. The classification aims to facilitate clinical, experimental, and epidemiological studies, ultimately improving patient outcomes. The 2016 CNS WHO is predicated on combined phenotypic and genotypic classification, with diagnostic terms reflecting both histopathological and genetic features. This approach provides a more dynamic and biologically homogeneous classification, guiding patient management and therapeutic decisions.The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) represents a significant advancement over its 2007 predecessor, incorporating molecular parameters alongside histological features to define many tumor entities. This update restructures diffuse gliomas, medulloblastomas, and other embryonal tumors, and introduces new entities defined by both histology and molecular features. Key changes include the addition of brain invasion as a criterion for atypical meningioma and a soft tissue-type grading system for solitary fibrous tumor/hemangiopericytoma. The classification aims to facilitate clinical, experimental, and epidemiological studies, ultimately improving patient outcomes. The 2016 CNS WHO is predicated on combined phenotypic and genotypic classification, with diagnostic terms reflecting both histopathological and genetic features. This approach provides a more dynamic and biologically homogeneous classification, guiding patient management and therapeutic decisions.